Clinical trials: Liver Tumors
Hepatocellular Carcinoma
HCC Screening Using DNA Methylation Changes in ctDNA
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship.
- Trial name
- NCT03483922
- Testing
- ctDNA methylation in and it's Correlation wth Development and prediction of HCC
- Where
- Bangladesh
- Volunteers
- 403 people
- Sponsor
- HKGepitherapeutics
HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.
- Trial name
- Wondercel-UWD3 (NCT06653023)
- Testing
- Universal CAR-T cells injection for treating HCC and NSCLC, MMF Immunosuppression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Advanced Malignancies
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
- Trial name
- NCT03241173
- Testing
- INCAGN01949, Nivolumab, Ipilimumab
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- Incyte Biosciences International Sàrl
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Liver Cancer
Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer
Detect plasma Hsp90α concentration of liver cancer patients, healthy volunteers, benign liver diseases.
- Trial name
- NCT02324127
- Testing
- hsp90
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Cancer Metastatic to the Liver, Hepatocellular Carcinoma
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
This open-label study will evaluate the safety, tolerability, pharmacokinetics and effect on tumor growth following a single intralesional injection of PV-10 in subjects with either (a) hepatocellular carcinoma (HCC) that is not…
- Conditions
- Cancer Metastatic to the Liver, Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Ocular Melanoma
- Trial name
- NCT00986661
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- Provectus Biopharmaceuticals, Inc.
Hepatocellular Carcinoma, Hepatitis B
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
This is a Phase II study in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
- Conditions
- Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
- Trial name
- OUTREACH2 (NCT04710641)
- Testing
- MTL-CEBPA, Sorafenib
- Where
- 2 sites in United States, Singapore
- Volunteers
- 8 people
- Sponsor
- Mina Alpha Limited
Melanoma, Liver Cancer
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
- Conditions
- Melanoma, Liver Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT01935453
- Testing
- Recombinant hGM-CSF Herpes Simplex Virus Injection
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- OrienGene Biotechnology Ltd.
Hepatic Insufficiency, Liver Diseases
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.
- Trial name
- NCT07853040
- Testing
- INCB161734
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Carcinoma, Hepatocellular, Liver Neoplasms
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine whether the Litx™ treatment is safe and effective in treating inoperable hepatocellular carcinoma (HCC).
- Trial name
- NCT00122876
- Testing
- Photodynamic therapy, Talaporfin Sodium
- Where
- 9 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 25 people
- Sponsor
- Light Sciences Oncology
Hepatic Neoplasm Malignant
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients
Primary Objective: To evaluate the efficacy of SECOX regimen by adding oxaliplatin plus capecitabine to sorafenib versus sorafenib alone as palliative treatment for unresectable HCC patients to prolong overall survival (OS) for…
- Trial name
- SECOX (NCT01245582)
- Testing
- oxaliplatin (SR96669), capecitabine, sorafenib
- Sponsor
- Sanofi
Carcinoma, Hepatocellular, Carcinoma
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
The primary purpose of this study to continue follow-up of participants enrolled in the study E7080-M081-504 (NCT03663114) of lenvima capsules and to evaluate the overall survival of participants with hepatocellular carcinoma.
- Conditions
- Carcinoma, Hepatocellular, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms
- Trial name
- NCT04008082
- Testing
- Lenvatinib
- Where
- 2 sites in Japan
- Volunteers
- 412 people
- Sponsor
- Eisai Co., Ltd.
Liver Metastasis, Colorectal Neoplasms
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00068068
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- 6 sites in United States, Germany
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Carcinoma, Hepatocellular
A Study of PTX-9908 Injection for Non-resectable HCC With TACE
This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and…
- Trial name
- NCT03812874
- Testing
- PTX-9908 Injection
- Where
- Taiwan
- Sponsor
- TCM Biotech International Corp.
Hepatocellular Carcinoma
LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)
The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE…
- Trial name
- NCT03053596
- Testing
- DEB-TACE using anthracyclin loaded LifePearl™
- Where
- 7 sites in Belgium, France
- Volunteers
- 102 people
- Sponsor
- Terumo Europe N.V.
Cancer of the Liver, Liver Cancer
Ablation Confirmation Study
Prospective, single-arm, multicenter study that will generate clinical data using the NEUWAVE MicroWave Ablation System with AC (Ablation Confirmation) software in patients undergoing ablation of a soft tissue liver lesion.
- Conditions
- Cancer of the Liver, Liver Cancer, Neoplasms, Liver
- Trial name
- NCT03753789
- Testing
- Microwave Ablation
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Ethicon, Inc.
Solid Tumor Malignancies, Cancer, Solid Cancers
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with…
- Conditions
- Solid Tumor Malignancies, Cancer, Solid Cancers, Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT06883539
- Testing
- LXP1788 is administered intravenously via Port-A
- Where
- 2 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- LaunXP Biomedical Co., Ltd.
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Hepatocellular Carcinoma
Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. MB07133 is being developed for the treatment of inoperable HCC, using a platform technology known as HepDirectTM, which enables drugs to be targeted…
- Trial name
- NCT00073736
- Testing
- MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day
- Where
- 4 sites in United States, Hong Kong and 1 more
- Volunteers
- 28 people
- Sponsor
- Ligand Pharmaceuticals